In an industry that’s constantly evolving, staying ahead of the curve is crucial. Every breakthrough, every new piece of research can shape the future—and if you’re not in the loop, you risk falling behind. As 2025 approaches, now’s the perfect time to catch up on the insights and research that dominated 2024.
We’ve compiled the 10 most-read journal articles from our resource center to ensure you’re fully equipped for what’s next.
Physiologically Based Pharmacokinetic Absorption Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure
Pexidartinib is a systemic treatment for patients with tenosynovial giant cell tumor not amenable to surgery.
In this journal article, researchers developed a physiologically based pharmacokinetic model to determine the impact on drug exposure of dose timing with respect to meals, meal type, and caloric content.
Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report
These PBBM case studies enabled the industry to receive constructive feedback from global regulators and highlighted clear direction for future PBBM submissions for regulatory consideration.
Application of a new MDCKII-MDR1 cell model to measure the extent of drug distribution in vitro at equilibrium for prediction of in vivo unbound brain-to-plasma drug distribution
This study investigated an in vitro model using P-gp expressing MDCKII-MDR1 cells for predicting in vivo brain drug penetration.
With minor refinements, this in vitro approach could reduce the reliance on in vivo experiments, accelerating the pace of CNS drug discovery and promoting a more ethical research approach.
The AI‑driven Drug Design (AIDD) platform: an interactive multi‑parameter optimization system integrating molecular evolution with physiologically based pharmacokinetic simulations
If you have been curious about how to incorporate AI into your drug design program, this article provides an example.
In it, researchers describe the AIDD workflow and details of the methodologies involved therein. They use a dataset of triazolopyrimidine inhibitors of the dihydroorotate dehydrogenase from Plasmodium falciparum to illustrate how AIDD generates novel sets of molecules.
Prediction of the Liver Safety Profile of a First-in-Class Myeloperoxidase Inhibitor Using Quantitative Systems Toxicology Modeling
This journal article describes how the quantitative systems toxicology model, DILIsym(R), was used to predict the liver safety of verdiperstat.
Verdiperstat was predicted to be safe with minimal liver enzyme increases, and Phase 3 clinical trials confirmed similar ALT elevations between the treatment and placebo groups, validating the accuracy of QST modeling in predicting liver safety.
PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management
Many people don’t know that GastroPlus(R) offers a pregnancy-specific model. This study used physiologically based pharmacokinetic (PBPK) and pregnancy-specific PBPK (p-PBPK) models in GastroPlus to analyze the pharmacokinetics of lamotrigine (LTG) and efavirenz (EFV) in pregnant women.
Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report
This paper proposes best practices for measuring solubility, dissolution, precipitation, and permeability, and parameterizing PBBMs with these inputs. It also shares some PBBM case studies which were presented as part of the 2023 workshop and the discussions of the breakout sessions.
Pharmacokinetic Simulation Study: Exploring the Impact of Clinical Parameters on Lamotrigine for Different Patient Populations with Implications for Liver Function Assessment and Therapeutic Drug Monitoring
This study explores the pharmacokinetics of lamotrigine, a drug used for epilepsy and bipolar disorder, focusing on its potential for severe side effects like anticonvulsant hypersensitivity syndrome (AHS) and drug rash with eosinophilia and systemic symptoms (DRESS), particularly in patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
Predicting Human Dermal Drug Concentrations Using PBPK Modeling and Simulation: Clobetasol Propionate Case Study
Did you know GastroPlus can be used to simulate drug permeation through the skin?
In this journal article, researchers describe how quantitative in silico tools were leveraged to mechanistically predict the dermato-pharmacokinetics of compounds delivered from topical and transdermal formulations by integrating systems of rate equations that describe permeation through the formulation and layers of skin and pilo-sebaceous unit, and exchange with systemic circulation via local blood flow.
Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine’s Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes
This study highlights the capabilities of GastroPlus in developing and validating a PBPK model to investigate carbamazepine’s (CBZ) nonlinear pharmacokinetics and its potential for drug-drug interactions (DDIs).
By staying informed and tapping into the knowledge that’s already shaping the industry, you’ll be better prepared to tackle whatever comes next. Here’s to a year of growth, opportunity, and staying at the forefront of your field.
If you are curious about any of our software platforms mentioned in the articles above, let us know.